Latest Glenmark Pharmaceuticals S.A. Stories
MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A.
MUMBAI,India, July 3, 2014 /PRNewswire/ -- - GBR 830 is an antagonistic monoclonal antibody with first in class potential for the treatment of
- Glenmark's first novel molecule for an oncology indication - GBR 401 is a monoclonal antibody targeting CD19.
- A volcanic mudflow.